Fiche centre
Northwestern Memorial Hospital
Chicago — United States
Essais liés14clinical trials
VilleChicagolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07872982
Essais cliniques associés
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tricuspid Transcatheter Edge-to-Edge Repair (TEER) | Maladie coronarienne | À vérifier | NCT07586995 | TREAT TR — A Post-Market Assessment of the Safety and Performance of the TriClip™ System | RECRUITING |
| Recombinant Factor VIIa | Accident vasculaire cérébral | Phase 3 | NCT07227246 | FASTEST Part 2 — Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | RECRUITING |
| WATCHMAN FLX LAAC Device | Accident vasculaire cérébral | Non applicable | NCT04394546 | CHAMPION-AF Clinical Trial | ACTIVE_NOT_RECRUITING |
| Coronary and peripheral stents | Maladie coronarienne | À vérifier | NCT04573660 | AV-MDR — Abbott Vascular Medical Device Registry | RECRUITING |
| BrainProtect System | Maladie coronarienne | Non applicable | NCT07872982 | BrainProtect-guided, Real-time Cerebral Autoregulation Monitoring and Protection of Brain During Cardiac Surgery With Cardiopulmonary Bypass Requiring Heart-lung Machine | NOT_YET_RECRUITING |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| CABA-201 | Myasthénie | Phase 1/2 | NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06660394 | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | ACTIVE_NOT_RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06719141 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | ACTIVE_NOT_RECRUITING |
| Ocrevus Zunovo | SEP | À vérifier | NCT07710105 | Ocrevus Zunovo for MS: Mixed Methods | RECRUITING |
| GLP-1 | SEP | À vérifier | NCT07207148 | People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |